Search results
What Is Friedreich's Ataxia?
Verywell Health via Yahoo News· 1 year agoFriedreich's ataxia is a rare disease that affects your central nervous system. Individuals with late-onset Friedreich's ataxia (LOFA) and very...
FDA’s approval of Friedreich’s ataxia drug is a game changer for treatment of rare diseases
Quartz via Yahoo Finance· 1 year agoA drug to treat a rare neurological disorder has only had to jump through one hoop—read: clinical...
Reata Nears Breakout After Snagging FDA Blessing To Launch Its Friedreich's Ataxia Drug
Investor's Business Daily· 10 months agoReata Pharmaceuticals won the Food and Drug Administration's blessing to go ahead with production of...
Reata (RETA) Friedreich's Ataxia NDA Gets Priority Review
Zacks via Yahoo Finance· 2 years agoReata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder...
Reata Surges 12% Over Three Days; CEO Reflects On The Tricky Path To Launch A First-Ever Drug
Investor's Business Daily· 10 months agoReata Pharmaceuticals Chief Executive Warren Huff says Friedreich's ataxia is "the worst disease."...
Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug
Zacks via Yahoo Finance· 1 year agoSkyclarys is the first drug to be approved specifically for the treatment of Friedreich's ataxia and...
Reata (RETA) Stock Doubles This Year on Skyclarys FDA Nod
Zacks via Yahoo Finance· 1 year agoReata Pharmaceuticals’ RETA shares have more than doubled in 2023. The main reason for the surge is...
Biogen Skids On 'Low-Quality' Beat, Cuts Profit Guidance Following Reata Buyout
Investor's Business Daily· 6 months agoBiogen stock skidded Wednesday on a "low-quality" sales beat that relied on other revenue. But...
Why Reata Pharma Shares Are Skyrocketing Today
Benzinga via Yahoo Finance· 1 year agoThe FDA approved Reata Pharmaceuticals Inc's (NASDAQ: RETA) Skyclarys (omaveloxolone) for Friedreich's ataxia in adults and adolescents aged 16 and...
PTC Therapeutics Stock Tumbles: Company Stops Preclinical Gene Therapy Programs After Failed...
Benzinga via Yahoo Finance· 11 months agoPTC Therapeutics Inc (NASDAQ: PTCT) reported topline results from the MOVE-FA trial of vatiquinone...
